CMG Pharmaceutical Co., Ltd. (KOSDAQ:058820)

South Korea · Delayed Price · Currency is KRW

4,170.00

0.00 (0.00%)

Nov 2, 2026, 3:30 PM KST

CMG Pharmaceutical Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Revenue	115,709	105,229	99,100	93,907	82,197	58,623
Revenue Growth	22.15%	6.19%	5.53%	14.24%	40.21%	17.56%
Gross Profit	64,477	60,877	45,643	43,592	40,752	28,885
Operating Income	-3,629	-3,692	1,020	3,037	2,981	2,604
Net Income	4,640	-10,077	2,695	6,455	-388.14	3,051
Earnings Per Share	313.94	-700.00	54.78	460.00	-30.00	250.00
EPS Growth	-	-	-88.09%	-	-	-55.12%

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Pharmaceuticals	115,106	104,522	98,149	92,743	82,197	58,623
Other	862.84	991.93	969.18	1,251	-	-
Sales Between Divisions	-	-285.2	-18.84	-87.52	-	-
Total	115,709	105,229	99,100	93,907	82,197	58,623

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Cash & Investments	17,803	26,502	76,794	68,827	77,813	119,574
Total Debt	68,701	72,008	79,965	26,119	6,713	286.39
Net Cash (Debt)	-50,898	-45,506	-3,171	42,708	71,100	119,288
Net Cash Growth	-	-	-	-39.93%	-40.40%	119.02%
Net Cash Per Share	-3443.63	-3155.06	-201.82	3074.92	5119.10	9813.98

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Operating Cash Flow	-10,723	-11,020	290.09	3,938	4,938	2,823
Capital Expenditures	-38,729	-29,630	-28,098	-12,384	-8,382	-8,176
Free Cash Flow	-49,451	-40,650	-27,808	-8,446	-3,444	-5,352
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
Gross Margin	55.72%	57.85%	46.06%	46.42%	49.58%	49.27%
Operating Margin	-3.14%	-3.51%	1.03%	3.23%	3.63%	4.44%
Pretax Margin	4.02%	-11.25%	2.91%	7.17%	-1.53%	6.54%
Profit Margin	4.01%	-9.58%	2.72%	6.87%	-0.47%	5.21%
FCF Margin	-42.74%	-38.63%	-28.06%	-8.99%	-4.19%	-9.13%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2019
Period Ending	Nov '26 Nov 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '19 Dec 31, 2019
PE Ratio	13.28	-	91.13	51.85	-	193.46
PS Ratio	0.53	2.61	2.48	3.56	3.63	10.07